Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
about
Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry DiseaseThe development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.A modular approach to cardiac tissue engineering.Chimeric vessel tissue engineering driven by endothelialized modules in immunosuppressed Sprague-Dawley ratsApplication of an endothelialized modular construct for islet transplantation in syngeneic and allogeneic immunosuppressed rat models.Carboxyl-terminal truncations alter the activity of the human α-galactosidase APrevention of Lethal Murine Hypophosphatasia by Neonatal Ex Vivo Gene Therapy Using Lentivirally Transduced Bone Marrow CellsLentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice.In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.Gene therapy for fabry disease: a review of the literature.Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders.Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes.Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.Treatment of adult MPSI mouse brains with IDUA-expressing mesenchymal stem cells decreases GAG deposition and improves exploratory behavior.MicroRNA-24 regulates cardiac fibrosis after myocardial infarction.Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction.Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease.
P2860
Q33752595-7A7F5207-DCFE-415C-97E1-114B2D63B8F9Q33825097-06D8AB11-C1DE-4728-A4AA-0AC36A8C3505Q34163142-50917E90-52A5-4D0B-95ED-037AF21B9FA7Q34447366-E6CBBEF2-14B0-4FC0-9194-10AB9C448456Q35125065-E8088C44-0F32-459B-9A4E-172D2C00AE7FQ35125851-67A036C5-E739-459A-8879-AB1679869A0DQ35807632-5B0A8C8C-4BE7-461A-8052-17734A97ACF3Q36087322-BB8B21CB-D377-450C-9425-A54C6D64BEBAQ37038201-BEFD6EA6-5FD7-4E30-8BA2-277E8F0D69D5Q37591813-2184A19D-BB97-4BDA-8A9B-C750CC20E455Q38098070-66D7B48E-A32D-40B8-8B70-ABE8D4F4FC0EQ38245751-7E238A78-DACD-4F8B-997F-2BF486EB4204Q39413034-2FD7B4D9-AB80-476F-A3AD-8A984B9CC9E0Q40373588-B7DD2785-C99B-48BC-B429-C6052A0BC791Q41992406-20BD3371-DADE-4243-8A0A-B50D3DA067ABQ42089703-C24283A7-E21B-446D-909E-650732C7D1E0Q45855941-ADBE19A4-06F9-4663-A35B-75E68B8BD6D0Q45856748-6BD94EE3-0F49-4D86-A5CE-D976B66D226A
P2860
Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Efficient correction of Fabry ...... poietic stem/progenitor cells.
@en
Efficient correction of Fabry ...... poietic stem/progenitor cells.
@nl
type
label
Efficient correction of Fabry ...... poietic stem/progenitor cells.
@en
Efficient correction of Fabry ...... poietic stem/progenitor cells.
@nl
prefLabel
Efficient correction of Fabry ...... poietic stem/progenitor cells.
@en
Efficient correction of Fabry ...... poietic stem/progenitor cells.
@nl
P2093
P2860
P356
P1433
P1476
Efficient correction of Fabry ...... poietic stem/progenitor cells.
@en
P2093
Ramsubir S
Rasaiah VI
Siatskas C
Yoshimitsu M
P2860
P2888
P304
P356
10.1038/SJ.GT.3302839
P577
2006-08-24T00:00:00Z
P6179
1006093812